Variables | Training cohort | Validation cohort | ||
---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Overall survival | ||||
 IBM score | 8.636 (3.572–20.876) | < 0.001 | 4.479 (1.707–11.750) | 0.068 |
 T stage* | 0. 749 (0.423–1.325) | 0.321 | 2.747 (1.403–5.376) | 0.045 |
 M stage* | 1.072 (0.259–4.448) | 0.923 | 1.522 (0.120–19.340) | 0.746 |
 Clinical stage* | 1.345 (0.782–2.314) | 0.284 | 0.679(0.283–1.632) | 0.387 |
Progression-free survival | ||||
 IBM score | 11.471 (3.123–42.134) | < 0.001 | 6.341 (1.667–24.115) | 0.007 |
 Age | 0.991 (0.332–1.035) | 0.681 | 0.962 (0.902–1.026) | 0.238 |
 Sex (female vs. male) | 0.602 (0.283–1.280) | 0.188 | 0.429 (0.123–1.499) | 0.185 |
 M stage* | 1.917 (0.929–3.960) | 0.078 | 0.824 (0.237–2.862) | 0.761 |
 Clinical stage* | 1.006 (0.496–2.041) | 0.986 | 1.484 (0.505–4.363) | 0.473 |